| Solvent‐induced collapse of α‐synuclein and acid‐denatured cytochrome c AS Morar, A Olteanu, GB Young, GJ Pielak Protein Science 10 (11), 2195-2199, 2001 | 212 | 2001 |
| Sugar-induced molten-globule model PR Davis-Searles, AS Morar, AJ Saunders, DA Erie, GJ Pielak Biochemistry 37 (48), 17048-17053, 1998 | 102 | 1998 |
| PEGylation of proteins: A structural approach AS Morar, JL Schrimsher, MD Chavez Biopharm international 19 (4), 2006 | 73 | 2006 |
| Expression of 15N-labeled eukaryotic cytochrome c in Escherichia coli AS Morar, D Kakouras, GB Young, J Boyd, GJ Pielak Journal of Biological Inorganic Chemistry 4 (2), 220-222, 1999 | 63 | 1999 |
| Effects of Crowding by Mono-, Di-, and Tetrasaccharides on Cytochrome c−Cytochrome c Peroxidase Binding: Comparing Experiment to Theory AS Morar, X Wang, GJ Pielak Biochemistry 40 (1), 281-285, 2001 | 46 | 2001 |
| Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration S Morar-Mitrica, M Puri, A Beumer Sassi, J Fuller, P Hu, G Crotts, D Nesta MAbs 7 (4), 792-803, 2015 | 29 | 2015 |
| H-1 and N-15 hyperfine shifts of cytochrome c J Boyd, CM Dobson, AS Morar, RJP Williams, GJ Pielak Journal of the American Chemical Society 121 (39), 9247-9248, 1999 | 29 | 1999 |
| Formulation effects on opalescence of a high-concentration MAb JM Woods, D Nesta BioProcess Int 8 (9), 48-59, 2010 | 21 | 2010 |
| Evaluating Freeze–Thaw Processes in Biopharmaceutical Development M Puri, S Morar-Mitrica, G Crotts, D Nesta BioProcess International 13 (1), 34-45, 2015 | 19 | 2015 |
| Crowding by Trisaccharides and the 2:1 Cytochrome c−Cytochrome c Peroxidase Complex AS Morar, GJ Pielak Biochemistry 41 (2), 547-551, 2002 | 17 | 2002 |
| Low concentration antibody formulations G Crotts, S Morar-mitrica US Patent 10,537,638, 2020 | 14 | 2020 |
| An intercompany perspective on biopharmaceutical drug product robustness studies S Morar-Mitrica, ML Adams, G Crotts, C Wurth, PM Ihnat, T Tabish, ... Journal of Pharmaceutical Sciences 107 (2), 529-542, 2018 | 10 | 2018 |
| Differential scanning calorimetry (DSC) for biopharmaceutical development: Old concepts, new applications S Morar-Mitrica, D Nesta, G Crotts Biopharma Asia 2 (4), 44-55, 2013 | 6 | 2013 |
| in an Antibody Solution FORMULATIONS: Biophysical Approaches to the Detection and Characterization of Particles GlaxoSmithKline S Morar-Mitrica, C Brisbane, D Nesta, A Ketkar American Pharmaceutical Review 12 (7), 34, 2009 | 3 | 2009 |
| Applications of isothermal titration calorimetry and differential scanning calorimetry in biopharmaceutical formulation development JM Woods, M Puri, D Doucet, T Derrick, S Morar-Mitrica, D Nesta Biopharmaceutical Technologies. GlaxoSmithKline R&D, Edition AA, 2009 | 3 | 2009 |
| An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development Stages S Morar-Mitrica, T Pohl, D Theisen, B Boll, K Bechtold-Peters, ... Journal of pharmaceutical sciences 112 (5), 1476-1484, 2023 | 2 | 2023 |
| Tnf-alpha antigen-binding proteins GH Crotts, S Morar-mitrica US Patent App. 14/762,948, 2015 | 2 | 2015 |
| Low concentration antibody formulations G Crotts, S MORAR-MITRICA | | 2020 |
| Low concentration antibody formulations G Crotts, S MORAR-MITRICA | | 2014 |
| Effects of small molecule crowding on protein structure and equilibrium thermodynamics of protein-protein interaction AS Morar The University of North Carolina at Chapel Hill, 2001 | | 2001 |
